Short answer
PTC THERAPEUTICS, INC. (PTCT) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $361M (up 101.5% year over year) with net income of $83M.
Q2 2026 key financials · XBRL
- Revenue
- $361M
- +101.5% YoY · +32.3% QoQ
- Net income
- $83M
- +228.8% YoY · +3072.4% QoQ
- Operating margin
- 41.3%
- EPS (diluted)
- $0.93
- +224.0% YoY · +3200.0% QoQ
Source: XBRL data from the PTC THERAPEUTICS, INC. (PTCT) Q2 2026 10-Q on SEC EDGAR. USD.
PTC THERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash, equivalents and marketable securities $2.23B as of June 30, 2026
- Operating cash flow $70.1M vs $811.8M YoY
- Financing cash flow $218.3M vs $13.4M YoY, including $535.4M net 2031-note proceeds
- $328.8M used to repurchase $222.0M principal of 2026 Convertible Notes
- PROVE-FA open-label study planned for Q3 2026 following FDA feedback on vatiquinone NDA resubmission
Risk Factors
- New insider-trading disclosure: Director Michael Schmertzler adopted a Rule 10b5-1 sale plan on May 14, 2026
- Director trading plan: Up to 170,000 shares sale authorized through February 1, 2027
- New debt documentation: Indenture dated June 18, 2026, indicating newly issued or amended notes
- Compliance risk: Director and officer transactions must comply with insider-trading laws and the Company’s insider-trading policy
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PTC THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.